5-碘-2-硝基本酚 | 27783-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 5-碘-2-硝基本酚
• 英文名称: 5-iodo-2-nitrophenol
• CAS: 27783-55-7
• 化学式: C₆H₄INO₃
• mdl: MFCD12923199
• 分子量: 265.007
• InChiKey: NWDXJGPGCDHUJO-UHFFFAOYSA-N

物化性质

• 熔点：
  96 °C
• 沸点：
  312.9±32.0 °C(Predicted)
• 密度：
  2.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险类别：
  9
• 危险性防范说明：
  P261,P264,P270,P272,P273,P280,P301+P312+P330,P302+P352,P305+P351+P338+P310,P333+P313,P391,P501
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H315,H317,H318,H410
• 包装等级：
  III
• 储存条件：
  储存条件：2-8°C，避光、干燥密封保存。

反应信息

• 作为反应物：
  描述：

  5-碘-2-硝基本酚 在 硫酸 、 硝酸 作用下， 生成 5-iodo-2,4-dinitro-phenol
  参考文献：
  名称：

  Hodgson; Moore, Journal of the Chemical Society, 1927, p. 634

  摘要：

  DOI：
• 作为产物：
  描述：

  3-碘苯酚 在 硝酸 、 溶剂黄146 作用下， 反应 0.5h， 以10%的产率得到5-碘-2-硝基本酚
  参考文献：
  名称：

  Protein-specific localization of a rhodamine-based calcium-sensor in living cells

  摘要：

  一个小的合成钙传感器，可以通过利用生物正交的HaloTag标记策略，在活细胞中特异性地与任何感兴趣的蛋白质偶联。

  DOI：

  10.1039/c6ob00365f

文献信息

• Trifunctionalization of Aryl Iodides with Two Distinct Nitrogen and Carbon Electrophiles by Palladium/Norbornene Catalysis
  作者：Jing Wang、Hui Wang、Zihan Wang、Linqiang Li、Cheng Qin、Xinjun Luan

  DOI：10.1002/cjoc.202100467

  日期：2021.10

  highly chemo- and regioselective vicinal trifunctionalization of aryl iodides by palladium/norbornene (Pd/NBE) catalysis. The key feature of this new method is the introduction of two distinct nitrogen and carbon electrophiles, with a large gap in reactivity, for ortho-unsubstituted aryl iodides via an intermolecular and intramolecular C―H functionalization, respectively. Eight types of ipso terminations

  在此，我们报告了通过钯/降冰片烯 (Pd/NBE) 催化对芳基碘化物进行高度化学和区域选择性的邻位三官能化。这种新方法的关键特征是引入了两个不同的氮和碳亲电子的，在反应性有很大的差距，对邻-未被取代的芳基碘经由分别的分子内和分子CA€•ħ官能化，。八种类型的本位终端可以与两个邻位-amination和邻烷基化，得到多种多取代的苯并杂环支架。硅系衬底可以通过以下方式产生多官能芳烃单步操作。值得注意的是，这些产品表现出具有大斯托克斯位移的全色可调强荧光发射，并且产品 7r 可以作为荧光探针来特异性靶向活细胞中的溶酶体。
• [EN] GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS<br/>[FR] GELDANAMYCINE ET SES DERIVES POUVANT INHIBER UNE PROLIFERATION CANCEREUSE ET IDENTIFIER DE NOUVELLES CIBLES
  申请人：VAN ANDEL RES INST

  公开号：WO2005095347A1

  公开（公告）日：2005-10-13

  Geldanamycin derivatives that block the uPA-plasmin network and inhibit growth and invasion by glioblastoma cells and other tumors at femtomolar concentrations are potentially highly active anti-cancer drugs. GA and various 17-amino-17-demethoxygelddanamycin derivatives are disclosed that block HGF/SF-mediated Met tyrosine kinase receptor-dependent uPA activation at fM levels. Other ansamycins (macbecins I and II), GA derivatives, and radicicol required concentrations several logs higher (≥nM) to achieve such inhibition. The inhibitory activity of tested compounds was discordant with the known ability of drugs of this class to bind to hsp90, indicating the existence of a novel target(s) for HGF/SF -mediated events in tumor development. Methods of using such compounds to inhibit cancer cell activities and to treat tumors are disclosed. Such treatment with low doses of these highly active compounds provide an option for treating various Met-expressing tumors, in particular invasive brain cancers, either alone or in combination with conventional surgery, chemotherapy, or radiotherapy.

  盖尔达霉素衍生物可以在飞托摩尔浓度下阻断uPA-纤溶酶网络，抑制胶质母细胞瘤细胞和其他肿瘤的生长和侵袭，潜在地是高活性的抗癌药物。已披露了盖尔达霉素（GA）和各种17-氨基-17-去甲氧基盖尔达霉素衍生物，可以在飞托摩尔水平下阻断HGF/SF介导的Met酪氨酸激酶受体依赖的uPA激活。其他吖丝霉素类化合物（马克贝辛I和II）、盖尔达霉素衍生物和雷地可（radicicol）需要更高几个数量级（≥nM）的浓度才能实现这种抑制作用。经测试的化合物的抑制活性与该类药物已知结合到hsp90的能力不符，表明存在一种新的靶标，用于抑制HGF/SF介导的肿瘤发展事件。公开了使用这类化合物来抑制癌细胞活动和治疗肿瘤的方法。用这些高活性化合物的低剂量进行治疗为治疗各种表达Met的肿瘤提供了一种选择，特别是侵袭性脑癌，可以单独使用或与常规手术、化疗或放疗结合使用。
• Compositions and methods for treating cancer
  申请人：Mayers L. George

  公开号：US20060018908A1

  公开（公告）日：2006-01-26

  The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.

  这项发明涉及用于治疗或缓解癌症症状的组合物和方法。该发明的组合物和方法将超致死剂量的辐射（称为热点）直接作用于几乎所有癌细胞类型。
• Magnetic moment and atomic volume in supersaturated Fe–Cu solid solutions: <i>Ab initio</i>calculations compared with experiments
  作者：Wenqing Zhang、E. Ma

  DOI：10.1557/jmr.2000.0097

  日期：2000.3

  The properties of nonequilibrium face-centered-cubic (fcc) and body-centered-cubic (bcc) Fe–Cu alloys were studied using the first-principles full-potential linearized augmented plane wave method within the generalized gradient approximation. The ab initio calculation results are compared quantitatively with the magnetic moment and atomic volume observed for mechanically alloyed Fe_xCu_100–x (x = 0 to 100) supersaturated bcc and fcc solid solutions. The calculations show that Cu alloying leads to a small enhancement of the magnetic moment of bcc Fe. The fcc Fe moment, on the other hand, experiences a more pronounced increase into a high-spin state upon alloying with Cu. It reaches approximately the same value as that in the bcc alloys for all Cu concentrations where fcc solutions are obtained in experiments, corroborating previous ab initio calculations using different methods. The magnetic moment increases are accompanied by an atomic volume expansion. Both the calculated moment and volume behavior are in good agreement with those measured for fcc and bcc Fe–Cu solutions. The magnetovolume expansion upon magnetic interaction between the alloyed Fe and Cu, rather than the positive heat of mixing, constitutes the primary reason for the atomic volume increase observed.

  采用广义梯度近似的第一原理全电势线性化增强平面波法研究了非平衡面心立方（fcc）和体心立方（bcc）铁铜合金的性质。将 ab initio 计算结果与机械合金化的 FexCu100-x（x = 0 至 100）过饱和 bcc 和 fcc 固溶体的磁矩和原子体积进行了定量比较。计算结果表明，铜合金化导致 bcc 铁的磁矩略有增强。另一方面，与铜合金化后，fcc 铁的磁矩会更明显地增加到高自旋态。在实验中获得 fcc 溶液的所有铜浓度下，fcc 铁的磁矩都达到了与 bcc 合金大致相同的值，这与之前使用不同方法进行的 ab initio 计算结果相吻合。磁矩的增加伴随着原子体积的膨胀。计算得出的磁矩和体积行为与 fcc 和 bcc 铁-铜溶液的测量结果十分吻合。合金铁和铜之间的磁相互作用导致的磁体积膨胀，而不是正混合热，是观察到的原子体积增加的主要原因。
• Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
  申请人：Mayers L. George

  公开号：US20050058652A1

  公开（公告）日：2005-03-17

  The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.

  这项发明涉及治疗或缓解癌症症状的组合物和方法。该发明的组合物和方法将被称为“Hot-Spots”的超致死剂量辐射直接作用于几乎所有癌细胞类型。